Objective: This study conducted a systematic review of randomized controlled trials in order to evaluate the efficacy and safety of Baofukang Suppository (保妇康栓) combined with interferon on cervical high-risk human papillomavirus (HR-HPV) infection. Methods: Data comes from China National Knowledge Infrastructure (CNKI), Wanfang database, the VIP information database, Chinese Biomedical Literature Database, PubMed, Cochrane Library, Web of Science and Embase. Primary and secondary outcome measures were extracted from 13 included randomized controlled trials: number of HR-HPV turning negative and effective, time of HPV turning negative, duration of abnormal vaginal secretions and adverse events. Results: Baofukang Suppository combined with interferon were better than interferon alone in improving the negative rate of HR-HPV (RR=1.42, 95％CI [1.28, 1.58], P<0.00001) and the effective rate of HR-HPV (RR=1.3, 95％CI [1.24, 1.37], P<0.00001), time of HR-HPV turning negative (MD=-8.32, 95％CI [-9.17, -7.47], P<0.00001), duration of abnormal vaginal secretions (MD=-8.95, 95％CI [-11.34, -6.56], P<0.00001). However, there was no statistical difference in improving inflammatory factor (TNF-α: SMD=-0.49, 95％CI [-1.02, 0.03], Z=1.83, P=0.07; IL-6: SMD=-13.69, 95％CI [-41.98, 14.6], Z=0.95, P=0.34) and adverse events (RR=-0.73, 95％CI [0.48, 1.11, P=0.15) between two groups. Conclusion: The results showed that the efficacy of Baofukang Suppository combined with interferon were better than interferon alone in improving the negative and effective rate of HR-HPV, shortening the time of HR-HPV turning negative and duration of abnormal vaginal secretion and reducing adverse events.